References
- Salmon SE. Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Semin Hematol 1973;10:135–44
- Broder S, Humphrey R, Drum M, et al. Impaired synthesis of polyclonal (non-para protein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma: role of suppressor cells. N Engl J Med 1975;293:887–92
- MacGregor RR, Negendank WC, Schreiber AD. Impaired granulocyte adherence in multiple myeloma: relationship to complement system, granulocyte delivery, and infection. Blood 1978;51:591–9
- Defronzo RA, Humphrey RL, Wright JR, et al. Acute renal failure in multiple myeloma. Medicine (Baltimore) 1975;54:209–23
- Misiani R, Remuzzi G, Bertani T, et al. Plasmapheresis in the treatment of acute renal failure in multiple myeloma. Am J Med 1979;66:684–8
- Brown WW, Hebert LE, Piering WF, et al. Reversal of chronic end-stage renal failure due to myeloma kidney. Ann Intern Med 1979;90:793–4
- Gordon DA, Pruzanski W, Ogryzlo MA, et al. Amyloid arthritis simulating rheumatoid disease in five patients with multiple myeloma. Am J Med 1973;55:142–54
- Stone MJ, Frendel EP. The clinical spectrum of light chain myeloma: a study of 35 patients with special reference to the occurrence of amyloidosis. Am J Med 1975:58:601–19
- Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842–54
- Bergsagel DE. Treatment of plasma cell myeloma. Ann Rev Med 1979;30:431–43
- McIntyre OR. Current concepts in cancer: multiple myeloma. N Engl J Med 1979;301:193–6
- Case DC Jr, Lee DJ III, Clarkson BD. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine, and BCNU:M-2 protocol. Am J Med 1977;63: 897–903
- Salmon SE, Hamburger AW, Soehnlen B, et al. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 1978;298:1321–7
- Alexanian R, Gehan E, Haut A, et al. Unmaintained remissions in multiple myeloma. Blood 1978;51:1005–11
- Fahey JL, Barth WF, Solomon A. Serum hyperviscosity syndrome. JAMA 1965;192:464–7
- Wright DJ, Jenkins DE Jr. Simplified method for estimation of serum and plasma viscosity in multiple myeloma and related disorders. Blood 1970;36:516–22
- Mackenzie MR, Fudenberg HH. Macro-globulinemia: an analysis for forty patients. Blood 1972;39:874–89
- Migliore PJ, Alexanian R. Monoclonal gammopathy in human neoplasia. Cancer 1968;21:1127–31
- Avasthi PS, Erickson DG, Williams RC Jr, et al. Benign monoclonal gammaglobulinemia and glomerulonephritis. Am J Med 1977;62:324–9
- Evans RS, Baxter E, Gilliland BC. Chronic hemolytic anemia due to cold agglutinins: a 20-year history of benign gammopathy with response to chlorambucil. Blood 1973:42:463–70
- Maldonado JE, Velosa JA, Kyle RA, et al. Fanconi syndrome in adults: a manifestation of a latent form of myeloma. Am J Med 1975;58:354–64
- Smithline N, Kassirer JP, Cohen JJ. Light-chain nephropathy: renal tubular dysfunction associated with light-chain proteinuria. N Engl J Med 1976;294:71–4
- Axelsson U. An eleven-year follow-up on 64 subjects with M-components. Acta Med Scand 1977;201:173–5
- Pick AI, Shoenfeld Y, Frohlichmann R, et al. Plasma cell dyscrasia: analysis of 423 patients. JAMA 1979;241:2275–8
- Kyle RA. Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am J Med 1978;64:814–26